Epilepsy - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H2 2018’, provides an overview of the Epilepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epilepsy

- The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects

- The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Epilepsy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Epilepsy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adamas Pharmaceuticals Inc

Advicenne SA

Aeolus Pharmaceuticals Inc

Aequus Pharmaceuticals Inc

Affectis Pharmaceuticals AG

AMO Pharma Ltd

Anavex Life Sciences Corp

Aphios Corp

Aquestive Therapeutics ...

Adamas Pharmaceuticals Inc

Advicenne SA

Aeolus Pharmaceuticals Inc

Aequus Pharmaceuticals Inc

Affectis Pharmaceuticals AG

AMO Pharma Ltd

Anavex Life Sciences Corp

Aphios Corp

Aquestive Therapeutics Inc

Aucta Pharmaceuticals LLC

Bausch Health Companies Inc

Bial - Portela & Ca SA

BioCrea GmbH

Biogen Inc

BioHealthonomics Inc

Biovista Inc

Biscayne Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cavion LLC

Celgene Corp

Cellix Bio Pvt Ltd

Cerecor Inc

Crossject SA

Eisai Co Ltd

Genus Lifesciences Inc

Gilead Sciences Inc

Glialogix Inc

Grifols SA

GW Pharmaceuticals Plc

Idorsia Pharmaceutical Ltd

India Globalization Capital Inc

Insys Therapeutics Inc

Ionis Pharmaceuticals Inc

Iproteos SL

Johnson & Johnson

Knopp Biosciences LLC

Lead Discovery Center GmbH

Lotus Pharmaceutical Co Ltd

Marinus Pharmaceuticals Inc

Medicure Inc

Medlab Clinical Ltd

Mitochon Pharmaceuticals Inc

MMJ PhytoTech Limited

NeuCyte Inc

Neurelis Inc

Neurocrine Biosciences Inc

NeuroCycle Therapeutics GmbH

Neuron Biopharma SA

NoNO Inc

Novartis AG

OPKO Health Inc

Ovid Therapeutics Inc

Pairnomix LLC

Pfizer Inc

Promius Pharma LLC

PTC Therapeutics Inc

reMYND NV

Sage Therapeutics Inc

Saniona AB

SciFluor Life Sciences LLC

Serina Therapeutics Inc

Shire Plc

Simcere Pharmaceutical Group

SK Biopharmaceuticals Co Ltd

Suda Pharmaceuticals Ltd

Sumitomo Dainippon Pharma Co Ltd

Takeda Pharmaceutical Co Ltd

Taro Pharmaceutical Industries Ltd

The Cell-Factory BVBA

UCB SA

Ultragenyx Pharmaceutical Inc

Upsher-Smith Laboratories Inc

Vitality Biopharma Inc

Xenon Pharmaceuticals Inc

XERIS Pharmaceuticals Inc

Zogenix Inc

Zynerba Pharmaceuticals Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Epilepsy – Overview 7

Epilepsy – Therapeutics Development 8

Epilepsy – Therapeutics Assessment 32

Epilepsy – Companies Involved in Therapeutics ...

Table of Contents

Table of Contents 2

Introduction 6

Epilepsy – Overview 7

Epilepsy – Therapeutics Development 8

Epilepsy – Therapeutics Assessment 32

Epilepsy – Companies Involved in Therapeutics Development 46

Epilepsy – Drug Profiles 83

Epilepsy – Dormant Projects 372

Epilepsy – Discontinued Products 382

Epilepsy – Product Development Milestones 384

Appendix 393

List of Tables

List of Tables

Number of Products under Development for Epilepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Epilepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Products under Development by Companies, H2 2018 (Contd..5), H2 2018

Products under Development by Companies, H2 2018 (Contd..6), H2 2018

Products under Development by Companies, H2 2018 (Contd..7), H2 2018

Products under Development by Companies, H2 2018 (Contd..8), H2 2018

Products under Development by Companies, H2 2018 (Contd..9), H2 2018

Products under Development by Companies, H2 2018 (Contd..10), H2 2018

Products under Development by Universities/Institutes, H2 2018

Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..3), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..3), H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Epilepsy – Pipeline by Adamas Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by Advicenne SA, H2 2018

Epilepsy – Pipeline by Aeolus Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by Aequus Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by Affectis Pharmaceuticals AG, H2 2018

Epilepsy – Pipeline by AMO Pharma Ltd, H2 2018

Epilepsy – Pipeline by Anavex Life Sciences Corp, H2 2018

Epilepsy – Pipeline by Aphios Corp, H2 2018

Epilepsy – Pipeline by Aquestive Therapeutics Inc, H2 2018

Epilepsy – Pipeline by Aucta Pharmaceuticals LLC, H2 2018

Epilepsy – Pipeline by Bausch Health Companies Inc, H2 2018

Epilepsy – Pipeline by Bial - Portela & Ca SA, H2 2018

Epilepsy – Pipeline by BioCrea GmbH, H2 2018

Epilepsy – Pipeline by Biogen Inc, H2 2018

Epilepsy – Pipeline by BioHealthonomics Inc, H2 2018

Epilepsy – Pipeline by Biovista Inc, H2 2018

Epilepsy – Pipeline by Biscayne Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by Catalyst Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by Cavion LLC, H2 2018

Epilepsy – Pipeline by Celgene Corp, H2 2018

Epilepsy – Pipeline by Cellix Bio Pvt Ltd, H2 2018

Epilepsy – Pipeline by Cerecor Inc, H2 2018

Epilepsy – Pipeline by Crossject SA, H2 2018

Epilepsy – Pipeline by Eisai Co Ltd, H2 2018

Epilepsy – Pipeline by Genus Lifesciences Inc, H2 2018

Epilepsy – Pipeline by Gilead Sciences Inc, H2 2018

Epilepsy – Pipeline by Glialogix Inc, H2 2018

Epilepsy – Pipeline by Grifols SA, H2 2018

Epilepsy – Pipeline by GW Pharmaceuticals Plc, H2 2018

Epilepsy – Pipeline by Idorsia Pharmaceutical Ltd, H2 2018

Epilepsy – Pipeline by India Globalization Capital Inc, H2 2018

Epilepsy – Pipeline by Insys Therapeutics Inc, H2 2018

Epilepsy – Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by Iproteos SL, H2 2018

Epilepsy – Pipeline by Johnson & Johnson, H2 2018

Epilepsy – Pipeline by Knopp Biosciences LLC, H2 2018

Epilepsy – Pipeline by Lead Discovery Center GmbH, H2 2018

Epilepsy – Pipeline by Lotus Pharmaceutical Co Ltd, H2 2018

Epilepsy – Pipeline by Marinus Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by Medicure Inc, H2 2018

Epilepsy – Pipeline by Medlab Clinical Ltd, H2 2018

Epilepsy – Pipeline by Mitochon Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by MMJ PhytoTech Limited, H2 2018

Epilepsy – Pipeline by NeuCyte Inc, H2 2018

Epilepsy – Pipeline by Neurelis Inc, H2 2018

Epilepsy – Pipeline by Neurocrine Biosciences Inc, H2 2018

Epilepsy – Pipeline by NeuroCycle Therapeutics GmbH, H2 2018

Epilepsy – Pipeline by Neuron Biopharma SA, H2 2018

Epilepsy – Pipeline by NoNO Inc, H2 2018

Epilepsy – Pipeline by Novartis AG, H2 2018

Epilepsy – Pipeline by OPKO Health Inc, H2 2018

Epilepsy – Pipeline by Ovid Therapeutics Inc, H2 2018

Epilepsy – Pipeline by Pairnomix LLC, H2 2018

Epilepsy – Pipeline by Pfizer Inc, H2 2018

Epilepsy – Pipeline by Promius Pharma LLC, H2 2018

Epilepsy – Pipeline by PTC Therapeutics Inc, H2 2018

Epilepsy – Pipeline by reMYND NV, H2 2018

Epilepsy – Pipeline by Sage Therapeutics Inc, H2 2018

Epilepsy – Pipeline by Saniona AB, H2 2018

Epilepsy – Pipeline by SciFluor Life Sciences LLC, H2 2018

Epilepsy – Pipeline by Serina Therapeutics Inc, H2 2018

Epilepsy – Pipeline by Shire Plc, H2 2018

Epilepsy – Pipeline by Simcere Pharmaceutical Group, H2 2018

Epilepsy – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Epilepsy – Pipeline by Suda Pharmaceuticals Ltd, H2 2018

Epilepsy – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2018

Epilepsy – Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018

Epilepsy – Pipeline by Taro Pharmaceutical Industries Ltd, H2 2018

Epilepsy – Pipeline by The Cell-Factory BVBA, H2 2018

Epilepsy – Pipeline by UCB SA, H2 2018

Epilepsy – Pipeline by Ultragenyx Pharmaceutical Inc, H2 2018

Epilepsy – Pipeline by Upsher-Smith Laboratories Inc, H2 2018

Epilepsy – Pipeline by Vitality Biopharma Inc, H2 2018

Epilepsy – Pipeline by Xenon Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by XERIS Pharmaceuticals Inc, H2 2018

Epilepsy – Pipeline by Zogenix Inc, H2 2018

Epilepsy – Pipeline by Zynerba Pharmaceuticals Inc, H2 2018

Epilepsy – Dormant Projects, H2 2018

Epilepsy – Dormant Projects, H2 2018 (Contd..1), H2 2018

Epilepsy – Dormant Projects, H2 2018 (Contd..2), H2 2018

Epilepsy – Dormant Projects, H2 2018 (Contd..3), H2 2018

Epilepsy – Dormant Projects, H2 2018 (Contd..4), H2 2018

Epilepsy – Dormant Projects, H2 2018 (Contd..5), H2 2018

Epilepsy – Dormant Projects, H2 2018 (Contd..6), H2 2018

Epilepsy – Dormant Projects, H2 2018 (Contd..7), H2 2018

Epilepsy – Dormant Projects, H2 2018 (Contd..8), H2 2018

Epilepsy – Discontinued Products, H2 2018

Epilepsy – Discontinued Products, H2 2018 (Contd..1), H2 2018

List of Figures

List of Figures

Number of Products under Development for Epilepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Epilepsy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports